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Abstract
Human immunodeficiency virus type 1 (HIV-1) genetic diversity poses a challenge to reliable viral load monitoring.
Discrepancies between different testing platforms have been observed, especially for non-clade-B virus. Therefore we
compare, in antiretroviral therapy (ART)-naı ¨ve South African subjects predominantly infected with HIV-1 clade-C, three
commercially available assays: the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0 by Roche (CAP/CTM v2.0), the
BioMe ´rieux NucliSens Version 2.0 Easy Q/Easy Mag (NucliSens v2.0) and the Roche COBAS Amplicor HIV-1 Monitor Test
Version 1.5 (Amplicor v1.5). Strong linear correlation was observed and Bland-Altman analyses showed overall good
agreement between the assays with mean viral load differences of 0.078 log cp/ml (NucliSens v2.0 – Amplicor v1.5), 0.260
log cp/ml (CAP/CTM v2.0 – Amplicor v1.5) and 0.164 log cp/ml (CAP/CTM v2.0 – NucliSens v2.0), indicating lower mean viral
load results for the Amplicor v1.5 and higher mean readings for the CAP/CTM v2.0. Consistent with observations following
previous comparisons of CAP/CTM v2.0 versus Amplicor v1.5, the CAP/CTM v2.0 assay detected low-level viremia (median
65 cp/ml) in more than one-third of those in whom viremia had been undetectable (,20 cp/ml) in assays using the
NucliSens platform. These levels of viremia are of uncertain clinical significance but may be of importance in early detection
of ART resistance in those on treatment. Overall the three assays showed good comparability of results but with consistent,
albeit relatively small, discrepancies for HIV-1 clade-C samples, especially in the low-viremic range that should be taken into
account when interpreting viral load data.
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Introduction
In clinical care the plasma HIV RNA viral load is widely used as
a marker of disease progression [1] and is crucial to monitor
efficacy of antiretroviral therapy. Research studies in the field of
HIV infection also rely upon accurate measurements of HIV RNA
levels that are reproducible and comparable temporally and
geographically across the broad range of genetic diversity of HIV-
1. Since the emergence of the HIV epidemic several commercial
nucleic acid amplification platforms have been developed to
measure the viral load and are now available worldwide. As signal
and nucleic acid amplification methods depend on sequence
specific primers and probes, HIV subtype-specific polymorphisms
in the target regions can affect hybridization and hence
compromise the quantitative measurement. Recent studies have
shown discrepancies between different assays, especially for non-
clade B specimens [2–5].
Approximately 50% of all HIV-1-infections are caused by HIV-
1 group M clade-C globally, whereas clade-A and clade-B HIV-
infections as the second and third most prevalent subtypes account
for only about 10% each [6]. This uneven distribution is driven by
the fact that the vast majority of HIV infections are located in sub-
Saharan Africa, where clade-C overwhelmingly predominates.
More than 10 million people are living with HIV in this region.
Most HIV research, and a disproportionate fraction of viral load
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therefore focused mainly on non-C-clade samples. Thus, the C-
clade strain is relatively underrepresented in most studies despite
being the most relevant subgroup from a global perspective. In the
published comparisons between the new generation viral load
assays, the proportion of C-clade specimens is also underrepre-
sented.
To address this gap, we performed a comparison between three
different commercial testing platforms for HIV-1 viral load
monitoring using predominantly clade-C samples from South
Africa, the country with more HIV infections than any other. We
conducted a direct comparison between the COBAS AmpliPrep/
COBAS TaqMan HIV-1 Test version 2.0 by Roche (CAP/CTM
v2.0), the BioMe ´rieux NucliSens Version 2.0 Easy Q/Easy Mag
(NucliSens v2.0) and the Roche COBAS Amplicor HIV-1
Monitor Test Version 1.5 (Amplicor v1.5) for HIV-1 RNA
quantification in blood plasma from a cohort of HIV-1 clade-C-
infected patients.
Materials and Methods
Study subjects and sample collection
In a cohort of 220 asymptomatic, HAART-naı ¨ve post-natal
women attending a pediatric immunization clinic at the Prince
Mshiyeni Memorial Hospital in Umlazi, Durban, South Africa
between 2012–2013 (median age 26.3 yrs, median CD4 count
538/mm
3, median VL 6,100 cp/ml), we had noted an unexpect-
edly high proportion with low viral loads using the NucliSens v2.0.
We therefore selected a subset (n=44), including samples selected
to represent the range of viral loads observed, in order to
determine whether, and if so to what degree, the NucliSens v2.0
was reading lower than the CAP/CTM v2.0. In a selected subset
of 13 of these subjects, whose viral loads were low (,1000 cp/ml)
using the NucliSens v2.0, samples were studied from two separate
visits to the clinic in order to increase the power of the study for
comparison in the low viremic range. Plasma was separated from
EDTA whole blood and stored at 280uC until testing. Viral load
measurements were performed on frozen samples without
previous freeze-thaw cycles to ensure consistent sample viability
for these two assays.
To compare these two currently available assays with the
Amplicor v1.5 assay previously widely used, we selected a
representative subset of samples (n=38) that were collected
between 2002–2005 from a similar cohort of antenatal women
(n=328, median age 27.3 yrs, median CD4 count 399/mm
3,
median viral load 29,350 cp/ml) recruited from Prince Mshiyeni
Memorial Hospital and St Mary’s Hospital in Durban, South
Africa. In this cohort, viral loads had originally been determined in
2002–2005 from fresh EDTA plasma using the Amplicor v1.5
assay.
Overall, samples were studied from 82 different subjects. HIV-
status was determined using the Determine and Uni-Gold HIV
rapid tests. For those subjects with undetectable viral load results,
HIV-status was confirmed by Western blot.
Ethics statement
Written informed consent was obtained from all participating
individuals, and the Biomedical Research Ethics Administration of
the University of KwaZulu-Natal and the institutional review
board at the University of Oxford approved the study.
HIV-1 Subtype analysis
The HIV-1 genotype was determined by sequencing in 72 of the
82 subjects as described previously [7] and confirmed to be
subtype C in all cases. The Gag sequence data used for this study
were submitted to GenBank (GenBank accession numbers
KJ948566-KJ948637).
Viral load measurement
The three commercial kits were used to determine the viral
loads of the samples according to the manufacturer’s instructions
at the Global Clinical Viral Laboratory, Durban, South Africa, a
good clinical laboratory practice (GCLP) compliant laboratory
accredited through the South African National Accreditation
System (SANAS).
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0
(CAP/CTM v2.0)
The CAP/CTM v2.0 uses the fully automated COBAS
AmpliPrep Instrument for specimen processing and the COBAS
TaqMan Analyzer for amplification and detection with a reported
linear range of 20–10,000,000 cp/ml. The sample input was
850 ml EDTA-plasma for this study.
NucliSens Version 2.0 Easy Q/Easy Mag (NucliSens v2.0)
The NucliSens v2.0 uses a p24 Gag targeted nucleic acid
sequence-based amplification (NASBA) associated with molecular
beacon probes for detection of amplified nucleic acid products.
RNA was purified from 100 ul patient EDTA plasma using the
fully automated EasyMag extractor. Subsequently isothermic
cDNA amplification and detection was performed on the
automated EasyQ instrument with a dynamic range of 100–
10,000,000 cp/ml with a detection limit of 20 cp/ml.
Table 1. Data summary for viral load results as determined by the Amplicor v1.5, NucliSens v2.0 and CAP/CTM v2.0 assay.
Comparison n Mean log VL (cp/ml) SD of mean Bland-Altman analysis
(95% CI) Bias SD of bias 95% Limits of Agreement
NucliSens v2.0 35 4.587 (4.301, 4.873) 0.8321 0.078 0.5349 20.9705, 1.126
Amplicor v1.5 35 4.509 (4.201, 4.817) 0.8975
CAP/CTM v2.0 34 4.702 (4.451, 4.953) 0.7188 0.2603 0.4783 20.6771, 1.198
Amplicor v1.5 34 4.441 (4.120, 4.763) 0.9209
CAP/CTM v2.0 88 3.584 (3.283, 3.886) 1.423 0.1642 0.4373 20.6929, 1.021
NucliSens v2.0 88 3.420 (3.107, 3.733) 1.478
doi:10.1371/journal.pone.0103983.t001
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(Amplicor v1.5)
The Amplicor v1.5 is an end-point RT-PCR assay targeting a
consensus region in the gag gene. It was used as the standard (not
the ultra-sensitive) assay with a linear range of 400–750,000 cp/ml
using 200 ul of EDTA-plasma.
Statistical Analysis
All results were converted to cp/ml and transformed to log cp/
ml for further statistical analysis using GraphPad Prism v6.0.
Samples with viral loads below the detection limit of the assay were
assigned the value of the lower limit of detection, i.e. 20 cp/ml (log
cp/ml=1.30) for NucliSens v2.0 and CAP/CTM v2.0. To
determine the linear relationship between the assays the Spearman
correlation coefficient (r) was calculated. Bland-Altman analysis
was used to assess the agreement between the different methods of
viral load measurement [8]. The difference between the results for
the same sample (a1–a2) was plotted against the average of the two
measurements ((a1–a2)/2). The bias between the assays was
calculated as the mean m of the difference between the two
measurements (a1–a2) and its standard deviation (s) was calculated.
The 95% limits of agreement between the assays were determined
as m61.96 s.
Results
Summary statistics
For some samples viral load measurements were only available
for 2 out of the 3 platforms being compared, hence the number of
analyzed samples varies between the different comparisons. Data
were available for n=35 samples for the comparison between
Amplicor v1.5/NucliSens v2.0, n=34 for Amplicor v1.5/CAP/
CTM v2.0 and n=88 for the CAP/CTM v2.0/NucliSens v2.0
comparison as shown in Table S1. The average viral loads and
standard deviations as well as the results for the Bland-Altman
analysis for the different comparisons are summarized in Table 1.
Performance of NucliSens v2.0 versus CAP/CTM v2.0
The mean log viral load result for the n=87 samples used for
this comparison was 3.420 log cp/ml (3.107–3.733 log cp/ml) for
the NucliSens v2.0 and 3.584 log cp/ml (3.283–3.886 cp/ml) for
the CAP/CTM v2.0. In this dataset NucliSens v2.0 and CAP/
CTM v2.0 showed a significant linear correlation (Spearman’s
correlation coefficient r=0.957, p,0.0001, Figure 1A).
In the Bland-Altman model (Figure 2A) the two assays showed
high levels of agreement with a mean difference of m=0.1642 log
cp/ml s=0.4373. Thus the NucliSens v2.0 tends to give slightly
lower readings. Within this dataset there were 6 outliers (6.8% of
samples) that were beyond the limits of agreement for this dataset,
5 of which read higher on the CAP/CTM v2.0. These outliers are
evenly distributed throughout the range of viral loads. Of note, out
of the 88 samples that were available for the comparison between
the NucliSens v2.0 and CAP/CTM v2.0 assays, the output by the
NucliSens v2.0 was ,20 cp/ml (undetectable) for 18 samples.
However, with the CAP/CTM v2.0 assay, a quantitative result
was generated for 7 of these samples (Table S1), with a median
viral load of 65 cp/ml as determined by the CAP/CTM v2.0. All
samples that had a readout of ,20 cp/ml on the CAP/CTM v2.0
also measured as ,20 cp/ml on the NucliSens v2.0.
Performance of NucliSens v2.0 versus Amplicor v1.5
For the n=35 samples available for this comparison, the mean
log viral load results were 4.587 log cp/ml (4.301–4.873 log cp/ml)
for the NucliSens v2.0 and 4.509 cp/ml (4.201–4.817 log cp/ml)
for the Amplicor v1.5. The assays showed significant linear
correlation within the range of tested samples (r=0.824, p,
0.0001, Figure 1B). All analyzed samples were in the quantitative
range of the assays.
Bland-Altman analysis showed close overall agreement between
the assays with a bias of m=0.078 log cp/ml (s=0.5439)
indicating slightly higher measurements for the NucliSens v2.0
compared to the Amplicor v1.5 (figure 2B). The 95% limits of
agreement were 20.9705 and 1.126 log cp/ml showing 5 outliers
(14.3% of samples) that did not follow a specific distribution
throughout the range of viral loads that were represented in this
comparison.
Performance of CAP/CTM v2.0 versus Amplicor v1.5
Mean viral load results for the n=34 samples analyzed for this
comparison are 4.702 log cp/ml (4.451–4953 log cp/ml) for the
CAP/CTM v2.0 and 4.441 log cp/ml (4.120–4.763 log cp/ml) for
the Amplicor v1.5. Linear correlation across the analyzed log VL
range that was within the quantitative limits of the two assays was
strong (r=0.835, p,0.0001).
In the Bland-Altman model the mean difference between the
two assays was m=0.2603 log cp/ml (s=0.4783), reading higher
on the CAP/CTM v2.0 with 95% limits of agreement of -0.6771
log cp/ml and 1.198 log cp/ml. Three of the 4 outliers (12% of
samples) are in the lower log VL range and read higher on the
CAP/CTM v2.0.
Discussion
The reliable quantification of HIV-1 RNA viral load is a critical
tool in HIV clinical care and research [9]. However, the high
variability of the HIV-genome poses a great challenge to
commercial assays to produce accurate measurements across the
wide spectrum of HIV-1 subtypes. Previous studies have shown
problems of under-estimation of viral load results by different
testing platforms especially for non-B-clade samples [10–14].
Earlier studies evaluating the previous versions of the NucliSens
assays, namely the NucliSens QT and its successors the NucliSens
EasyQ v1.1 and v1.2, have shown underestimation of viral loads in
non-clade-B samples [2,5,10,14] and specifically clade-C samples
[12,13]. However, another study from South Africa found close
agreement between the NucliSens EasyQ v1.1 and the Roche
Amplicor v1.5 [4].
More recent studies evaluated the new version of the
BioMerieux assay, the NucliSens v2.0. A study in China found
improved performance in measuring non-B-clade samples [15],
but no C-clade samples were included in this study. Another study
tested different HIV-subtypes including 17 clade-C samples and
found close agreement between the NucliSens v2.0 and the Abbott
m2000 RealTime HIV-1 assay [11]. In a study from Gabon, the
NucliSens v2.0 showed sub-optimal sensitivity in detecting
circulating recombinant forms (CRFs) [16].
The need to adequately detect diverse HIV-subtypes has been
appreciated and manufacturers are aiming to improve subtype
inclusivity of their assays constantly. The latest version of the
Figure 1. Linear correlation between (A) NucliSens v2.0 versus CAP/CTM v2.0 (B) NucliSens v2.0 versus Amplicor v1.5 (C) CAP/CTM
v2.0 versus Amplicor v1.5. Solid lines represent the fitted linear regression curve, dashed lines show the equality line and dotted lines represent
lower limits of detection of the respective assay.
doi:10.1371/journal.pone.0103983.g001
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labeled hybridization probes that target both the gag and LTR
regions to improve coverage of HIV-1 sequence polymorphisms
[17]. Indeed, the sensitivity of this assay to detect non-B-clade
virus has improved compared to its predecessor version and other
methods including the NucliSens v1.2 and v2.0 and the Amplicor
v1.5 [3,5]. However, in the same studies the possibility of ‘‘over-
quantification’’ due to the usage of two dual-labeled probes has
been raised and is supported by showing constantly higher mean
quantitative values for this assay compared to the other established
methods. Yet, while the one study analyzed no HIV-1 clade-C
samples at all, the other included only 1 clade-C sample.
We therefore performed this study in a South African cohort of
HIV-1 clade-C infected subjects to compare recent versions of
three widely used testing platforms, the CAP/CTM v2.0,
NucliSens v2.0 and the Amplicor v1.5.
Our direct comparison between the NucliSens v2.0 and the
Amplicor v1.5 has shown overall strong linear correlation
(r=0.824, p,0.0001) and agreement (mean difference,
m=0.078 cp/ml) with slightly higher readings on the NucliSens
platform especially for samples in the range of 3–5 log cp/ml. The
CAP/CTM v2.0 measured consistently higher than the Amplicor
v1.5 with a bias of m=0.2603 log cp/ml which is consistent with
other studies [18,19].
We also observed higher VL measurements for the CAP/CTM
v2.0 compared with the NucliSens v2.0 with a mean difference of
m=0.1642 log cp/ml with strong linear correlation (r=0.957, p,
0.0001). This bias for clade-C virus between these two assays is
lower than the difference that was observed in a study testing
clade-B9, BC and AE samples from China measuring a mean
difference of 0.588 log IU/ml [3]. Of note, for 7 of 18 samples
defined as ,20 cp/ml by the NucliSens v2.0 in our study, the
CAP/CTM v2.0 generated measurements in the low-viremic
range (median 65 cp/ml). Similar findings were observed in
plasma from 109/502 C-clade infected subjects whose viral load
was undetectable on the v1.5 assay, and detectable when retested
using the v2.0 [18]. Other studies have also observed high
sensitivity for the CAP/CTM v2.0 in the region of the lower limits
of detection for different subtypes [20,21].
Further factors to consider include the volume of sample
required for the respective assays and costs. For this study we have
used the minimum required sample input volume of 100 ml plasma
for the NucliSens assay whereas 850 ml were used for the CAP/
CTM v2.0. Lower sample volume requirements may be of
particular interest in relation to pediatric studies. However, using
the minimum volume for the NucliSens assay might compromise
the sensitivity of the assay in the low-viremic range as stated by the
manufacturer. At current prices the cost of the NucliSens assay is
substantially lower than that of the CAP/CTM v2.0, a factor
which is always of considerable relevance, but especially so in
resource limited settings. It remains open to discussion whether the
failure to detect low level viremia in a minority of those samples
measuring ,20 cp/ml on the NucliSens is of clinical significance
and justifies increased costs of using the CAP/CTM v2.0 assay.
Indeed, the introduction of novel more sensitive assays has led to
an increase in low-positive viral load results of patients on
antiretroviral therapy that has raised the question of which
clinically relevant threshold should be used as an end-point for
treatment efficacy [21–23].
It is important to note the limitations of this study. First, for the
comparisons between the Amplicor v1.5 versus the CAP/CTM
v2.0 and the NucliSens v2.0, the numbers studied in this dataset
were restricted by sample availability, and thus those analyses were
underpowered to draw strong conclusions. Second, none of the
samples included in the comparisons with the Amplicor v1.5 had a
viral load below 3 log cp/ml, and therefore this did not allow the
performance of the Amplicor v1.5 to be assessed in the low viremic
range. Third, plasma samples for the comparison with the
Amplicor v1.5 were collected between 2002–2005 and run on
the Amplicor v1.5 immediately but were stored at 280uC until
run on the NucliSens v2.0 and CAP/CTM v2.0. The higher
measurements on both of the two recent platforms compared to
the Amplicor v1.5 might therefore be an underestimate. Finally,
the low sample input volume of 100 ml for the NucliSens v2.0
assay may reduce the sensitivity of that assay, as mentioned above.
In conclusion, despite overall good agreement, there are
discrepancies between the different testing platforms compared
in this study using predominantly HIV-1 clade-C samples,
especially in the low-viremic range. These differences have to be
taken into account in clinical care, but also when comparing viral
load results in clinical trials and other scientific studies. The
decision to use one assay or the other, will certainly depend on the
performance of the assay. But overall costs and throughput rates
should also be considered, especially in resource limited settings.
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